{"id":"alks-9072","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALKS 9072 combines a mu opioid agonist with an opioid antagonist in a fixed-dose formulation intended to maintain analgesic efficacy while deterring misuse through antagonist activity if the formulation is tampered with or taken in ways other than intended. This abuse-deterrent approach aims to address the opioid crisis while preserving therapeutic pain relief benefits.","oneSentence":"ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:20.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain"}]},"trialDetails":[{"nctId":"NCT01469039","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":623},{"nctId":"NCT01626456","phase":"PHASE3","title":"A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2012-06","conditions":"Schizophrenia","enrollment":478},{"nctId":"NCT01493726","phase":"PHASE1","title":"A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":88},{"nctId":"NCT02320032","phase":"PHASE1","title":"An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2014-12","conditions":"Schizophrenia","enrollment":140},{"nctId":"NCT01895452","phase":"PHASE3","title":"An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2013-07","conditions":"Schizophrenia","enrollment":291},{"nctId":"NCT02636842","phase":"PHASE1","title":"A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-12","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALKS 9072","genericName":"ALKS 9072","companyName":"Alkermes, Inc.","companyId":"alkermes-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential. Used for Moderate to severe acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}